Fig. 5: GP38 + G_C- vaccine is protective in VSV-based surrogate challenge model.

Challenge study to determine the utility of a VSV-based surrogate challenge virus when looking at vaccine protective efficacy. a Experimental timeline. Groups of 10 mice, 5 male and 5 female, were immunized with 10 µg/dose of BPL inactivated vaccines adjuvated with 5 µg of PHAD in 2% SE per dose as indicated by the syringe with the rhabdovirus containing multiple glycoproteins. Challenge of 5E5pfu of surrogate virus is indicated by the syringe with a VSV with a singular set of glycoproteins. Red blood drops indicate the days blood was taken, and the skull denotes the conclusion of the study when any surviving mice were sacrificed. Created with Biorender.com. b Table of vaccine groups and representative colors. GP38 EC₅₀ titers pre-challenge (c) and post-challenge (f). Error bars indicate the mean with standard deviation (SD) for groups of 5 mice with samples run in triplicate. d Average group weight curves. Error bars indicate SD. e Viral RNA copies in the blood as determined by VSV-N qPCR. LOD, limit of detection. Error bars indicate the mean with SD. Results show the combination of two independent experiments; hollow symbols represent the first experiment and symbols with a black outline represent the second experiment. An ordinary one-way ANOVA with Tukey’s Multiple Comparison Test was used to determine statistical differences between groups at each time point for EC₅₀ titers and viremia (c, e, f). Two-way ANOVA with Tukey’s Multiple Comparison Test was used to determine statistical differences between groups for the weight curves (d). All comparisons between groups not listed on the EC₅₀ or weight change graphs had 4-star significant difference. (****P < 0.0001; ***P < 0.0002; **P < 0.0021; *P < 0.0332; ns not significant).